Kilitch Drugs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE729D01010
NSEID: KILITCH
BSEID: 524500

INR

331.50

-13.5 (-3.91%)

BSENSE

Apr 11, 12:51 PM

BSE+NSE Vol: 1.68 k

Click here to access the older version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Divi's Lab.

Medico Remedies

Cipla

Kilitch Drugs

Sun Pharma.Inds.

Torrent Pharma

Sakar Healthcare

Nectar Lifesci.

Albert David

Mankind Pharma

Ind-Swift Labs.

Why is Kilitch Drugs (India) Ltd ?

Poor Management Efficiency with a low ROE of 5.61%

The company has been able to generate a Return on Equity (avg) of 5.61% signifying low profitability per unit of shareholders funds

Stock is technically in a Mildly Bearish range

The technical trend has deteriorated from Sideways on 07-Apr-25 and has generated -3.37% returns since then
Multiple factors for the stock are Mildly Bearish like MACD, KST and DOW

With ROE of 8.7, it has a Expensive valuation with a 2.9 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -6.82%, its profits have risen by 33.9% ; the PEG ratio of the company is 0.8

Despite the size of the company, domestic mutual funds hold only 0% of the company

Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kilitch Drugs for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Kilitch Drugs

-9.41%

-0.16

41.35%

SENSEX

0.45%

0.03

14.48%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

24.42%

EBIT Growth (5y)

43.05%

EBIT to Interest (avg)

2.98

Debt to EBITDA (avg)

3.98

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.64

Tax Ratio

29.47%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

7.41%

ROE (avg)

5.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.93

EV to EBIT

25.94

EV to EBITDA

22.42

EV to Capital Employed

3.24

EV to Sales

2.90

PEG Ratio

0.84

Dividend Yield

ROCE (Latest)

8.53%

ROE (Latest)

8.69%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

NET SALES(Q)

At Rs 56.17 cr has Grown at 42.6% (vs previous 4Q average

PAT(Q)

At Rs 5.96 cr has Grown at 44.8%

PBDIT(Q)

Highest at Rs 8.74 cr.

PBT LESS OI(Q)

Highest at Rs 6.52 cr.

-5What is not working for the Company

INTEREST(Q)

At Rs 1.40 cr has Grown at 139,999,900.00%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 6.28 cr

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.20 times

Loading Valuation Snapshot...

Here's what is working for Kilitch Drugs

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 6.52 cr has Grown at 191.1%

over average PBT of the previous four quarters of Rs 2.24 Cr

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Net Sales - Quarterly

At Rs 56.17 cr has Grown at 42.6% (vs previous 4Q average)

over average Net Sales of the previous four quarters of Rs 39.38 Cr

MOJO Watch

Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 5.96 cr has Grown at 44.8%

over average PAT of the previous four quarters of Rs 4.12 Cr

MOJO Watch

Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly

Highest at Rs 56.17 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly

Highest at Rs 8.74 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 6.52 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Here's what is not working for Kilitch Drugs

Interest - Quarterly

At Rs 1.40 cr has Grown at 139,999,900.00%

Quarter on Quarter (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Cash and Cash Equivalents - Half Yearly

Lowest at Rs 6.28 cr

in the last six half yearly periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debtors Turnover Ratio- Half Yearly

Lowest at 2.20 times

in the last five half yearly periods

MOJO Watch

Company's pace of settling its Debtors has slowed

Debtors Turnover Ratio